Researchers at the University of Lethbridge recently declared the benefits of CBD as a potential aid in blocking the cells that enter the body from COVID-19 after promising results from a study. The study was conducted in April and published in the peer journal Preprints with the results being released in a non-peer-reviewed, preclinical study entitled ‘In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues’. The results were startling to say the least and shows how CBD could help with COVID-19. How?
The study works to develop cannabis therapies to help treat specific diseases.
Researchers conducted the study by using artificial 3D models or oral, airway and intestinal tissues coupled with a limited sample of high CBD cannabis sativa extracts modulate ACE2 gene expression and ACE2 protein levels.
Sativa Group Plc (NEX:SATI) is the UK’s leading quoted CBD Wellness and medicinal cannabis group with five operating subsidiaries. Goodbody Botanicals provides CBD products online and to retail markets including pharmacies, wellness stores and grocers. Goodbody Wellness is a high-street retail brand with dedicated CBD Wellness stores providing a premium shopping experience to consumers. Tessellate Collective is a direct-selling network marketing platform servicing consumers at home. Phytovista laboratories provides independent testing of CBD products to both external customers and fellow Group businesses. Sativa Grow holds a Controlled Drug licence and cultivates cannabis plants to fulfill its partnership agreement with King’s College London to research the impact of cannabinoids on inflammation and respiratory conditions.